Current disease status-Recurrent leukemia - Page 6 of 8 Posts on Medivizor
Navigation Menu

Current disease status-Recurrent leukemia Posts on Medivizor

Good response rates to venetoclax in patients previously treated with ibrutinib

Posted by on Jan 12, 2018 in Leukemia | 0 comments

In a nutshell This study examined venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL) previously treated with ibrutinib (Imbruvica). Researchers reported good disease control and a low rate of side effects venetoclax after ibrutinib. Some background Targeted therapy is the standard treatment of CLL. This includes the Bruton...

Read More

A new treatment combination for patients with relapsed Philadelphia chromosome positive leukemia

Posted by on Dec 30, 2017 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the combination of blinatumomab (Blincyto) and a tyrosine kinase inhibitor in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia. This study concluded that this combination was safe and effective for this group of patients.  Some background Philadelphia...

Read More

CAR-T cell therapy and infection risk

Posted by on Dec 16, 2017 in Leukemia | 0 comments

In a nutshell This study examined infection risk in leukemia and lymphoma patients treated with CAR-T cell therapy, a new type of immunotherapy. Researchers reported that infection rates were comparable to other salvage therapies.  Some background Chimeric antigen receptor (CAR) T-cell therapy helps the immune system to fight cancer cells. In...

Read More

A review of venetoclax for previously treated CLL

Posted by on Dec 2, 2017 in Leukemia | 0 comments

In a nutshell This study reviewed evidence on venetoclax (Venclexta) for previously treated chronic lymphocytic leukemia (CLL). Some background Targeted therapy is the standard treatment of CLL. This includes the BCL2 inhibitor therapy venetoclax. BCL2 inhibitor therapy blocks a protein called BCL2 involved in leukemia cell growth. Venetoclax has...

Read More

Gender affects outcomes of rituximab-based treatment

Posted by on Nov 16, 2017 in Leukemia | 0 comments

In a nutshell This study examined the effect of gender on treatment outcomes with chemo-immunotherapy for chronic lymphocytic leukemia (CLL). Researchers reported better survival and disease progression outcomes for female patients receiving rituximab-based (Rituxan) therapy.  Some background Men are more likely to develop CLL than women....

Read More

Inside the First FDA-Approved CAR-T Cell Therapy

Posted by on Nov 8, 2017 in Leukemia | 0 comments

Video Information: The first CAR T-cell therapy to receive FDA approval, CTL019 (Kymriah) was recently approved for children and young adults with B-cell acute lymphoblastic leukemia (ALL) that is refractory or has relapsed at least twice. Expert Dr. Michael Deinginger joins Patient Power Founder Andrew Schorr to explain CAR T-cell...

Read More

Stepping-up dosing approach for ofatumumab is safe and reduces administration time

Posted by on Nov 7, 2017 in Leukemia | 0 comments

In a nutshell This study tested the safety of ofatumumab (Arzerra) when administered using a stepping-up dosing approach. The approach was found to be safe and well tolerated. Some background Chemotherapy and immunotherapy are usually the first-line treatment of CLL. In cases of disease relapse, alternative treatment options are usually explored....

Read More

Long-term outcomes of allogeneic stem cell transplantations in young high-risk CLL patients

Posted by on Oct 5, 2017 in Leukemia | 0 comments

In a nutshell This study examined predictors of outcomes with stem cell transplantation from a donor (allo-SCT) for chronic lymphocytic leukemia (CLL). Researchers reported good long-term outcomes for young high-risk CLL patients treated with allo-SCT. Patients with matched sibling donors showed better outcomes compared to those with matched unrelated...

Read More

Side effects of ibrutinib and idelalisib treatment

Posted by on Sep 22, 2017 in Leukemia | 0 comments

In a nutshell In this review, the authors look at the most common adverse events related to ibrutinib and idelalisib, B-cell inhibitors. The study concluded that both ibrutinib and idelalisib are effective at treating B-cell cancers, and the side effects are within a normal range compared to other similar treatments. Some background Ibrutinib and...

Read More

Pembrolizumab in patients with chronic lymphocytic leukemia with Richter’s transformation

Posted by on Sep 21, 2017 in Leukemia | 0 comments

In a nutshell This study examined the safety and effectiveness of pembrolizumab in the treatment of chronic lymphocytic leukemia that has undergone Richter’s transformation. This study concluded that patients with Richter’s transformation responded to pembrolizumab.  Some background Chronic lymphocytic leukemia is a cancer where...

Read More